Quest Diagnostics Introduces AI Companion to Help Patients Understand and Act on Lab Test Results
MWN-AI** Summary
Quest Diagnostics has unveiled an innovative AI-powered feature called Quest AI Companion, designed to enhance patient understanding of laboratory test results. This tool, available through the secure MyQuest mobile app and portal, allows users to interact with the AI to analyze their test results, offering personalized and easy-to-understand explanations based on up to five years of historical lab data. This integration aims to address patient concerns regarding the complexity of medical terminologies and the implications of test values.
Nicole Antonson, Quest's vice president of digital solutions, emphasized the company's commitment to simplifying the patient experience, stating that the AI Companion empowers users to identify trends and potential health risks. This capability fosters more informed discussions with healthcare providers, enhancing the overall healthcare management process.
One of the key advantages of Quest AI Companion is its robust privacy framework. Operative within the HIPAA-compliant MyQuest platform, the tool alleviates patient fears regarding data security that are often associated with public AI tools. Patients can seamlessly ask the AI to clarify test names, medical jargon, and the significance of various lab values, all while maintaining control over their health data.
Developed in collaboration with Google Cloud, Quest AI Companion utilizes advanced AI technologies to refine data management and improve user experience. The initiative showcases a growing trend within the healthcare industry where AI is becoming integral to patient engagement and understanding.
While Quest AI Companion is a valuable educational resource, it is important to note that it does not replace professional medical advice. Patients are encouraged to continue communication with their healthcare providers regarding their health and lab results for comprehensive care. For access to these features, individuals can log into their MyQuest accounts.
MWN-AI** Analysis
Quest Diagnostics (NYSE: DGX) has launched the AI Companion, a significant innovation leveraging advanced AI technology to enhance patient engagement with their lab results. This feature, available through the secure MyQuest mobile platform, provides individuals personalized insights into their lab tests using data from the last five years. The integration of Google's Gemini technology exemplifies Quest's commitment to merging healthcare with cutting-edge digital solutions.
For investors, this development signals a strategic move that can potentially increase patient retention and stimulate growth in the digital health sector. The AI Companion prioritizes patient education—addressing a growing demand for understandable health information—thereby positioning Quest as a leader in patient-centered care. As individuals increasingly seek interactive and informative healthcare tools, this AI feature could differentiate Quest from its competitors, fostering brand loyalty among users who may otherwise feel overwhelmed by medical jargon.
However, market participants should also be aware of the broader landscape. AI integration, while beneficial, comes with challenges, including privacy concerns and the necessity of ongoing compliance with data protection regulations. Quest's assurance of HIPAA compliance and the avoidance of public AI interfaces will likely mitigate some skepticism among potential users, enhancing its credibility and adoption rates.
Investors should monitor user engagement metrics and feedback regarding the AI Companion, as its success will be a determining factor in Quest's ability to capture and expand its market share in the evolving healthcare ecosystem. Additionally, keeping an eye on partnerships with technology providers like Google Cloud may reveal further opportunities for growth, innovation, and potential revenue streams.
In conclusion, with its emphasis on AI-driven patient engagement, Quest Diagnostics not only strengthens its position in the diagnostics sector but also offers a promising avenue for investors seeking growth in healthcare technology.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
New feature based on Google's Gemini seamlessly analyzes up to five years of personal lab data to help explain results and uncover potential health risks
SECAUCUS, N.J., March 2, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced Quest AI Companion, a new AI-powered chat feature that helps individuals analyze, understand and act on their Quest laboratory test results with their healthcare provider.
Available now to all adult users of the company's secure, free patient mobile app and portal MyQuest, individuals can engage Quest AI Companion with questions about their test results and immediately receive personalized, easy-to-understand explanations, without leaving the integrated, HIPAA-compliant, MyQuest solution.
"Patients often tell us they want help simplifying and understanding their test results and what the results communicate about their health," said Nicole Antonson, vice president of digital solutions and interoperability, Quest Diagnostics. "For more than 50 years, Quest has been a trusted provider of laboratory results. Now, Quest AI Companion builds on this history and empowers patients to analyze their results and spot trends they can discuss with their healthcare provider, for smarter and simpler testing that illuminates a path to better health."
The new tool is unique because it seamlessly accesses and analyzes up to five years of an individual's lab data from Quest results reports to identify trends and patterns that may indicate health risks. As the Quest AI Companion operates within the secure MyQuest platform, individuals do not need to manually input their laboratory results into a public AI tool, avoiding concerns that may arise when sharing private health data with publicly accessible AI technologies. In addition, users can prompt the tool to define test names and medical terminology from their results reports, as well as translate the meaning of lab values, such as high, low, or within a reference range. Users can also prompt the AI Companion to assist with composing questions they can ask their healthcare provider, empowering patients to have more informed conversations with clinicians.
While the use of AI technologies is growing across the healthcare industry, recent reports suggest most individuals do not access Gen AI apps to analyze their personal health data. In a survey conducted by Quest about the use of AI, participants cited privacy and data security, alongside accuracy and reliability, as concerns about the use of AI.
"People want to understand their lab data, but not everyone feels comfortable uploading their health data to public AI platforms. Quest AI Companion empowers people to access the benefits of gen AI from a healthcare services provider they already know and trust to manage their most personal lab information," said Yuri Fesko, M.D., senior vice president and chief medical officer, Quest Diagnostics.
Powered by Google's Gemini family of models, Quest AI Companion is the result of a strategic collaboration with Google Cloud, established in March 2025. Through this relationship, Quest integrates Google Cloud's advanced AI technologies to streamline data management and improve customer experiences. The parties plan to continue to work together to aid patients and providers through innovation.
Individuals interested in Quest AI Companion can now access the service through their MyQuest account. Through MyQuest, patients can also schedule appointments, access test results and pay bills. For more information, visit MyQuest.QuestDiagnostics.com.
Quest AI Companion is a chat feature intended for individuals to analyze and understand their Quest laboratory test results with their healthcare provider. Users must be at least age 18. Quest AI Companion is not a substitute for professional medical advice or visits to a healthcare provider. Patients should continue to consult with a healthcare provider about test results and any symptoms they may be experiencing. The Quest AI Companion is for educational purposes only and not for use in the diagnosis of disease or other conditions. The information provided by this system should not be used to start, stop, or change any course of treatment unless advised by your healthcare provider.
About Quest Diagnostics
Quest Diagnostics works across healthcare to create a healthier world, one life at a time. We connect people, from clinicians to consumers, with laboratory insights that illuminate a path to better health. With a focus on delivering smarter, simpler testing, we help reveal new avenues to identify and treat disease, empower healthy behaviors and improve healthcare management. Quest Diagnostics serves half the physicians and hospitals in the United States and one in three American adults each year, and our nearly 57,000 employees work together to deliver diagnostic insights that inspire actions to transform lives. www.QuestDiagnostics.com
SOURCE Quest Diagnostics
FAQ**
How does the introduction of Quest AI Companion enhance the customer experience for patients using Quest Diagnostics Incorporated DGX's MyQuest platform in understanding their lab results?
What safeguards are in place to ensure privacy and security of patient data when using the AI features in Quest Diagnostics Incorporated DGX's Quest AI Companion?
Can you explain how Quest AI Companion utilizes up to five years of personal lab data to identify health trends, and what implications this has for patient care through Quest Diagnostics Incorporated DGX?
In what ways does the collaboration with Google Cloud improve the functions of Quest AI Companion, and how might this impact Quest Diagnostics Incorporated DGX's position in the healthcare technology space?
**MWN-AI FAQ is based on asking OpenAI questions about Quest Diagnostics Incorporated (NYSE: DGX).
NASDAQ: DGX
DGX Trading
-2.57% G/L:
$200.21 Last:
378,034 Volume:
$203.76 Open:
